SCHEDULE: Forbion Funds Take 6.1% Stake in Crescent Biopharma

Forbion Growth III PA B.V. and affiliated entities have reported a 6.1% beneficial ownership stake in Crescent Biopharma, Inc. following a recent private placement.

Summary

• ForGrowth III PA B.V., Forbion Growth Opportunities Fund III Cooperatief U.A., and Forbion Growth III Management B.V. (collectively, "Reporting Persons") have acquired a beneficial ownership stake in Crescent Biopharma, Inc.
• The Reporting Persons collectively own 1,677,852 Ordinary Shares, representing 6.1% of the company's outstanding shares.
• This ownership percentage is calculated based on a total of 27,556,767 Ordinary Shares outstanding, which includes 13,892,516 shares as of November 3, 2025, and an additional 13,664,251 shares issued on December 8, 2025, through a private placement.
• The Reporting Persons disclaim any intent to change or influence control of the issuer.

Sentiment

Score: 7

Explanation: The entry of a specialized biopharma investor like Forbion, coupled with a successful private placement, suggests confidence in Crescent Biopharma's long-term potential and provides necessary capital. However, the significant share issuance implies dilution for existing shareholders.

Positives

• A significant investment by a specialized growth fund like Forbion indicates confidence in Crescent Biopharma's future prospects and valuation.
• The private placement on December 8, 2025, provided Crescent Biopharma with additional capital, strengthening its financial position.
• Forbion's expertise in biopharma investments could bring strategic value beyond just capital.

Negatives

• The increase in outstanding shares due to the private placement (13,664,251 shares) represents significant dilution for existing shareholders.

Risks

• No specific risks are mentioned in this Schedule 13G filing beyond the general market risks associated with holding shares. The filing explicitly states the shares were not acquired for the purpose of changing or influencing control.

Future Outlook

NA

Industry Context

This filing indicates a significant investment by Forbion, a European life sciences venture capital firm, into Crescent Biopharma. Such investments are common in the biotechnology sector, where companies often require substantial capital for research, development, and clinical trials. A strategic investment from a specialized fund like Forbion can be seen as a validation of the company's technology or pipeline, potentially attracting further investor interest. The private placement suggests Crescent Biopharma is actively raising capital to fund its operations and growth initiatives.

Stakeholder Impact

• Shareholders: Existing shareholders experience dilution due to the issuance of 13,664,251 new shares in the private placement. However, the entry of a significant institutional investor may provide a positive signal and potentially stabilize or increase share value in the long term.
• Company (Crescent Biopharma): Benefits from increased capital from the private placement, which can fund ongoing operations, research, and development.

Key Dates

Recommendation

The entry of a significant institutional investor like Forbion is generally a positive signal, indicating external validation and providing capital. However, the substantial dilution from the private placement could exert downward pressure on the stock in the short term. Investors should hold to observe how the new capital is deployed and its impact on the company's pipeline and financial performance before making further investment decisions.

Keywords

Crescent Biopharma, Forbion Growth, Biopharma Investment, Schedule 13G, Beneficial Ownership, Private Placement, Biotechnology, Equity Stake